{
  "id": 20554127,
  "title": "SK Biopharma Unveils Growth Blueprint",
  "url": "https://urgent.news/2026/11/18/sk-biopharma-unveils-growth-blueprint",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-18T06:16:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=281604"
  },
  "original_language": "en",
  "account": "On November 17th, Lee Dong-hoon, the president of SK Biopharmaceuticals, unveiled the company's growth strategy at the Jefferies Global Healthcare Conference in London, marking its fourth consecutive year of attendance. SK Biopharmaceuticals, the sole South Korean pharmaceutical or biotech firm to present, showcased its core asset, cenobamate, which has witnessed a surge in prescribing, reaching over 300,000 patients globally since September.\n\nTo navigate the product lifecycle, the company is targeting broader indications and age groups, including generalized tonic-clonic seizures in patients 12 and older, as well as pediatric patients. In addition, SK Biopharmaceuticals aims to enhance patient convenience by introducing diversified formulations, such as an oral suspension.\n\nThe company's expansion into global markets is accelerating. Following the start of commercialization in China in March, cenobamate was launched in South Korea and Japan in November, establishing a sales network across the three Northeast Asian countries. SK Biopharmaceuticals has also sequentially introduced the product in Peru, Chile, and Brazil in Central and South America.\n\nTo bolster its central nervous system portfolio, SK Biopharmaceuticals is developing the epilepsy candidate, Opcalim, which it in-licensed in August. The drug is currently in Phase 2/3 clinical trials, with key results anticipated in the second half of the year. Key growth drivers identified by the company include oncology, leveraging next-generation modalities such as RNA-programmable therapy (RPT) and targeted protein degradation (TPD). The company plans to leverage its existing central nervous system research capabilities to explore oncology and uncover new therapeutic targets.\n\nAdditionally, SK Biopharmaceuticals announced the 'East-West Bridge' strategy, focusing on identifying promising technologies from Asian biotech companies and connecting them to global markets. Lee Dong-hoon highlighted the successful U.S. commercialization of cenobamate and emphasized the company's commitment to utilizing AI and open innovation to expedite the development of new drugs.",
  "summary": "Lee Dong-hoon, president of SK Biopharmaceuticals, presented the strategy on Nov. 17 local time at the Jefferies Global Healthcare Conference in London, the United Kingdom. SK Biopharmaceuticals, the only South Korean pharmaceutical or biotech company to give an on-site presentation, attended the ev",
  "key_points": [
    "SK Biopharma unveils growth strategy at Jefferies Global Healthcare Conference.",
    "Cenobamate reaches over 300,000 patients globally since September 2022.",
    "SK Biopharma targets broader indications, new formulations, and global expansion."
  ],
  "editors_take": "Expanding its core epilepsy asset into new age groups and geographic markets signals a shift toward diversifying its central nervous system portfolio and leveraging Asian biotech technologies for global scale.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}